KRAS and familial pancreatic carcinoma: Our study showed that in the subgroup analysis for pancreatic cancer, the KRAS was the most mutated gene (58% (95% CI: 31–83%)) and MAPK was the most altered pathway (31% (95% CI: 5–66%)).